LRRK2 and Parkinson disease: With next-generation sequencing becoming more readily available for people with PD and disease modification with targeted treatments including LRRK2 kinase inhibitors entering clinical trials [63,64], there is increased urgency to have a concrete set of functional parameters and experimental workflows available to help clinicians assess whether any given LRRK2 variant is likely to increase kinase activity and therefore a likely driver of the disease.